Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-03-21

Clinical Trial Update: Target Engagement and Response to Oxytocin [Phase 4]

View source ↗

Summary

A Phase 4 trial update evaluating oxytocin for schizophrenia, focusing on target engagement and clinical response. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Oxytocin (Oxytocin)

Snippet

Sponsor: University of California, Los Angeles | Conditions: Schizophrenia | Phase 4 | Status: COMPLETED